Barriers to clinical translation with diagnostic drugs

Journal of Nuclear Medicine

Volumn 54, Issue 3, 2013, Pages 329-332

  Josephson, Lee ^a   Rudin, Markus ^b,c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b ETH ZURICH   (Switzerland)

^c UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Imaging; IND; NDA

Indexed keywords

3' FLUOROTHYMIDINE F 18; AMYLOID BETA PROTEIN; APCITIDE TC 99M; BIOLOGICAL MARKER; DIAGNOSTIC AGENT; FLORBETAPIR F 18; FLUORODEOXYGLUCOSE F 18; GADOLINIUM CHELATE; IMCIROMAB PENTETATE; IODINATED CONTRAST MEDIUM; MANGAFODIPIR; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; RADIOACTIVE MATERIAL; SUPERPARAMAGNETIC IRON OXIDE; TETROFOSMIN TC 99M;

ALZHEIMER DISEASE; ARTICLE; CLINICAL RESEARCH; DIAGNOSTIC IMAGING; DRUG COST; DRUG MARKETING; DRUG RESEARCH; DRUG SAFETY; ECONOMIC ASPECT; HUMAN; MOLECULAR IMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

COSTS AND COST ANALYSIS; DRUG DISCOVERY; DRUGS, INVESTIGATIONAL; HUMANS; INVESTIGATIONAL NEW DRUG APPLICATION; MARKETING; RADIOISOTOPES; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84874838198     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.112.107615     Document Type: Article

References (11)

1. Nunn AD. The cost of developing imaging agents for routine clinical use. Invest Radiol. 2006;41:206-212. (Pubitemid 44406180)
2. Hoffman JM, Gambhir SS, Kelloff GJ. Regulatory and reimbursement challenges for molecular imaging. Radiology. 2007;245:645-660. (Pubitemid 350139065)
3. Frangioni JV. Translating in vivo diagnostics into clinical reality. Nat Biotechnol. 2006;24:909-913. (Pubitemid 44215378)
4. Vallabhajosula S. Positron emission tomography radiopharmaceuticals for imaging brain beta-amyloid. Semin Nucl Med. 2011;41:283-299.
5. Dzik-Jurasz A. Are targeted contrast agents realistically going to reach the clinic? Recent regulatory experience with targeted MRI contrast agents. Br J Radiol. 2006;79:870-872. (Pubitemid 44782001)
6. Bernd H, De Kerviler E, Gaillard S, Bonnemain B. Safety and tolerability of ultrasmall superparamagnetic iron oxide contrast agent: comprehensive analysis of a clinical development program. Invest Radiol. 2009;44:336-342.
7. Herper M. Why Eli Lilly's Alzheimer's imaging test is no breakthrough. Forbes. http://www.forbes.com/sites/matthewherper/2012/04/09/why-eli-lillys- alzheimers- imaging-test-is-no-breakthrough/. Published April 9, 2012. Accessed January 9, 2013.
8. Munos B. Lessons from 60 years of pharmaceutical innovation. Nat Rev Drug Discov. 2009;8:959-968.
9. Innovation or stagnation: challenge and opportunity on the critical path to new medical products. U.S. Food and Drug Administration Web site. http://www.fda. gov/ScienceResearch/SpecialTopics/CriticalPathInitiative/ CriticalPathOpportunitiesReports/ucm077262.htm. Published March 16, 2014. Updated July 20, 2010. Accessed January 9, 2012.
10. Rudin M. Imaging readouts as biomarkers or surrogate parameters for the assessment of therapeutic interventions. Eur Radiol. 2007;17:2441-2457.
11. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646-674.